VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
PDF
  • Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer [Elektronski vir] : updated analysis of the observational GioTag study
    Hochmair, Maximilian J ...
    Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential ... afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.
    Vir: Future oncology. - ISSN 1744-8301 (Vol. 15, iss. 25, Sep. 2019, str. 2905-2914)
    Vrsta gradiva - e-članek ; neleposlovje za odrasle
    Leto - 2019
    Jezik - angleški
    COBISS.SI-ID - 2048610929

    Povezava(-e):

    https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0346
    DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije
    DOI

Vnos na polico